The Million Hearts initiative, which aims to prevent a million cardiovascular events in a 5-year period, will focus on utilizing its partnerships with health systems and employers as it embarks upon its second phase, according to Janet Wright, MD, FACC, the program’s executive director.
The Million Hearts initiative, which aims to prevent a million cardiovascular events in a 5-year period, will focus on utilizing its partnerships with health systems and employers as it embarks upon its second phase, according to Janet Wright, MD, FACC, the program’s executive director.
Transcript (slightly modified)
What’s on the horizon for the Million Hearts initiative in the coming years?
What we’re excited about in Million Hearts 2022 is first and foremost that all of the partnerships and relationships that were either formed or deepened in the first 5 years are geared up and ready to go. In fact, their wheels are all turning. So we believe that although we likely will not have prevented a million events in the first 5 years, we are setting that aim again for the second 5 years, and we believe that the partnerships and many different types of relationships are the ticket to getting there.
In addition, there are some policies that started out in late 2011 and early 2012 that were conceptual, but now are actually pervasive across the country. So more and more places are basing their payment on value, and that allows performance of a whole team of people, really getting away from the fee-for-service model. And in addition, we have a number of best practices and lessons learned that we can layer on top of the existing evidence to make sure that improvements occur quickly.
Frankly, all 50 states have been involved in Million Hearts, including the District of Columbia, as well as many health systems. We will be looking to hospitals and academic medical centers as major partners in 2022, as well as employers who care deeply about the health of their employees.
Delayed Diagnoses, Oxygen Therapy Use Linked to Worse Outcomes in Patients With Fibrotic ILD
October 21st 2024Posters presented at the CHEST 2024 annual meeting revealed that delays in diagnosing fibrotic interstitial lung disease (ILD) can negatively impact overall survival, while supplemental oxygen therapy may exacerbate clinical burdens through increased rates of acute exacerbations and hospitalizations.
Read More
From Polypharmacy to Personalized Care: Dr Nihar Desai Discusses Holistic Cardiovascular Care
May 30th 2024In this episode of Managed Care Cast, Nihar Desai, MD, MPH, cardiologist and vice chief of Cardiology at the Yale School of Medicine, discusses therapies for cardiovascular conditions as they relate to patient adherence, polypharmacy, and health access.
Listen
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen